ABSTRACT Vitamin-D insufficiency and sarcoidosis are more common and severe in African Americans (AA) than Caucasians. In sarcoidosis, substrate-dependent extrarenal 1,25-dihydroxyvitamin-D (1,25-(OH) 2 D) production is thought to contribute to hypercalciuria and hypercalcemia, and vitamin-D repletion is often avoided. However, the anti-inflammatory properties of vitamin-D may also be beneficial. We prospectively examined serum vitamin-D levels, calcium balance, and the effects of vitamin-D repletion in 86 AA and Caucasian patients with biopsy-proven active sarcoidosis from the USA (US) and Italy (IT) in university-affiliated outpatient clinics. Clinical features, pulmonary function, and calciotropic hormones were measured. 16 patients with vitamin-D deficiency and normal serum ionized calcium (Ca 2+ ) were treated with oral ergocalciferol (50,000 IU/week) for 12 weeks. Baseline mineral parameters were similar in US (93% AA) and IT (95% Caucasian) patients irrespective of glucocorticoid treatment. Pulmonary dysfunction was less pronounced in IT patients. Nephrolithiasis (in 11% US, 17% IT patients) was associated with higher urinary calcium excretion. Vitamin-D deficiency was not more prevalent in patients compared to the respective general populations. As serum 25-hydroxyvitamin-D (25-OHD) rose postrepletion, serum 1,25-(OH) 2 D, γ-globulins, and the previously elevated angiotensin converting enzyme (ACE) levels declined. Asymptomatic reversible increases in Ca 2+ or urinary calcium/ creatinine (Ca/Cr) developed in three patients during repletion. In conclusion, Caucasian and AA patients show similar calcium and vitamin D profiles. The higher prevalence of hypercalciuria and nephrolithiasis in sarcoidosis is unrelated to endogenous vitamin-D levels. Vitamin-D repletion in sarcoidosis is generally safe, although calcium balance should be monitored. A hypothesis that 25-OHD repletion suppresses granulomatous immune activity is provided.
INTRODUCTION
Sarcoidosis is a multisystem disorder of undetermined etiology characterised by widespread non-caseating granulomatous inflammation. 1 Patients most commonly present with bilateral hilar lymphadenopathy, pulmonary infiltrates, and skin and ocular lesions, 2 although all organs may be involved. Activated macrophages and lymphocytes within the granuloma mediate extrarenal hydroxylation of 25-hydroxyvitamin D (25-OHD) to its active metabolite
Significance of study
What is already known about this subject?
▸ Both sarcoidosis and vitamin D deficiency are more common in African Americans than in Caucasians. ▸ The risk of calcium and vitamin D disturbance (hypercalcemia, hypercalciuria, and nephrolithiasis) may also differ between these two sarcoidosis patient populations. ▸ Physicians are ambivalent about giving vitamin D supplementation to patients with sarcoidosis for fear of mineral side effects.
What are the new findings?
▸ Sarcoidosis patients from two distinct ethnic and lifestyle backgrounds are largely similar in clinical, biochemical and mineral parameters. ▸ Nephrolithiasis is common in patients with sarcoidosis and largely driven by hypercalciuria, but the urinary calcium excretion rate is not significantly associated with serum vitamin D levels. ▸ The prevalence of vitamin D insufficiency is not higher in patients with sarcoidosis compared to the general racially matched population. ▸ Repletion of vitamin D stores in active sarcoidosis is generally safe and effective. Repletion is associated with consistent decreases in serum 1,25-(OH)2D levels and in the previously elevated serum ACE levels, suggesting suppression of granulomatous immune activity.
1,25-dihydroxyvitamin D (1,25-(OH) 2 D) independent of parathyroid hormone (PTH) or calcium regulation 3 but dependent on substrate (25-OHD) concentration. 4 Increased 1,25-(OH) 2 D, in turn, stimulates gastrointestinal calcium absorption and renal tubular calcium reabsorption, suppresses PTH production and osteoclast bone resorption, and promotes osteoblast bone mineralisation, thereby predisposing to the development of hypercalcemia, hypercalciuria and the formation of kidney stones. [5] [6] [7] [8] [9] Some have suggested that in sarcoidosis, vitamin D supplementation may induce hypercalcemia and hypercalciuria at doses normally insufficient to cause these alterations in healthy subjects. [10] [11] [12] [13] On the other hand, vitamin D also possesses antimicrobial and anti-inflammatory properties, and is known to modulate innate and adaptive immunity and mitigate granulomatous inflammation. 14 15 In this context, low endogenous vitamin D levels may potentially aggravate granulomatous inflammation in sarcoidosis while repletion of vitamin D levels may serve a beneficial adaptive role. The relative importance of these divergent mechanisms remains to be established.
Both sarcoidosis 16 and vitamin D deficiency 17 18 are more common and more severe in African Americans (AA) than in Caucasians. It is plausible that the risk of calcium and vitamin D disturbance (hypercalcemia, hypercalciuria, and nephrolithiasis) and the response to vitamin D supplementation may also differ between AA and Caucasian patients with sarcoidosis. To clarify this issue, we compared the calcium and vitamin D profiles between predominantly AA sarcoidosis patients in USA (US) and predominantly Caucasian sarcoidosis patients in Italy (IT), and examined whether vitamin D repletion raises the risk of hypercalcemia and hypercalciuria in these two cohorts.
SUBJECTS AND METHODS Subjects
A total of 44 patients were recruited from the Sarcoidosis Clinic at the Parkland Health & Hospital System, University of Texas Southwestern Medical Center in Dallas, Texas, USA. A total of 42 patients were recruited from the outpatient clinics of the Second University of Naples and the University Federico II of Naples in Naples, and the University of Padova in Padova, Italy. All patients had biopsy-proven active granulomatous disease consistent with the clinical diagnosis of sarcoidosis. Exclusion criteria included a history of malignancy, creatinine clearance <70 mL/min, and primary hyperparathyroidism.
Data from a separate multiethnic population-based study (Dallas Heart Study, DHS 19 ) consisting of 3447 Dallas residents without sarcoidosis including 1766 AA adults served as historical control for the assessment of vitamin D status and comparison with US patients with sarcoidosis. Another population-based cohort, the Progetto Veneto Anziani study (Pro.V.A) 20 consisting of 1927 Italian Caucasians without sarcoidosis served as historical control for the assessment of vitamin D status and comparison with IT patients with sarcoidosis. The Institutional Review Board of the University of Texas Southwestern Medical Center and the Ethics Committee of the University Hospital of the Second University of Naples approved the protocol. Written informed consent was obtained from all subjects.
Measurements
Demographic information, as well as clinical and laboratory profiles and treatment regimens, was reviewed. Fasting venous blood was drawn for serum chemistry, 25-OHD, 1,25-(OH) 2 D, and PTH, and a 24 h urine sample was collected for the measurement of the total volume, creatinine, and calcium. None of the patients was taking a pharmacological repletion dose of vitamin D. A few were taking over-the-counter vitamin D and or calcium supplements, which were stopped at least 1 week prior to undergoing study. Following baseline studies, 16 US patients with reduced serum 25-OHD (<75 nmol/L) who consented to undergo repletion therapy were prescribed ergocalciferol (50,000 IU) orally once a week for 12 weeks. Serum and 24 h urinary calcium levels were measured every 4 weeks. Adherence was assured by telephone calls, monthly office visits and by pill count at the end of the study.
Analytical procedures
Serum calcium, phosphorus, and creatinine were analyzed as part of a systematic multichannel analysis (SYNCHRON CX9 ALX system; Beckman Coulter Fullerton, California, USA). Serum 1,25-(OH) 2 D and PTH were measured by ELISA (IDS Immunodiagnostic Systems, Gaithersburg, Maryland, USA). Serum 25-OHD was measured by ELISA (IDS Immunodiagnostic Systems, Gaithersburg, Maryland, USA) or direct competitive chemiluminescence immunoassay (Liaison, DiaSorin, Turin, Italy). γ-Globulins were quantified on the basis of serum protein electrophoresis and immunofixation. Serum angiotensin converting enzyme (ACE) level was quantified on the basis of spectrophotometric quantification (absorbance at 340 nm) by the Mayo Laboratory. Urinary calcium was analyzed by atomic absorption spectrophotometry.
Statistical analysis
Normal distribution of the variables was established using histograms and the Wilk-Shapiro normality test. All results were reported as mean±SD. Two-sample t-tests were used to evaluate statistical significance among groups. Microsoft Excel and SAS V.9.4 (SAS Institute, Cary, North Carolina, USA) were used to perform statistical analysis.
RESULTS Demographics
Patient characteristics are shown in 
Glucocorticoid therapy
Forty-eight per cent of US patients and 74% of IT patients were taking prednisone. There were no statistically significant differences in baseline parameters between glucocorticoid-treated and untreated US patients (table 3) . Baseline FEV 1 was significantly higher in glucocorticoidtreated patients than untreated IT patients (2.95±0.96 vs 1.96±0.26 L, p=0.0001). Glucocorticoid-treated IT patients had slightly lower endogenous serum 25-OHD 
Comparison to ethnic populations
From the DHS database, 19 1766 AA subjects without sarcoidosis served as controls for US patients. The average serum 25-OHD level in US patients with sarcoidosis was higher than in DHS AA subjects (45±22 vs 37±17 nmol/L, p=0.04). The percentage of US patients with deficient 25-OHD levels (<50 nmol/L) was lower than that of DHS AA subjects (63.6% vs 80.6%, p=0.005), and the percentage with optimal (>75 nmol/L) 25-OHD levels was higher than that of DHS AA subjects (13.7% vs 2.8%, p<0.0001) (table 1). From the Pro.V.A database, 20 1927 Caucasian subjects without sarcoidosis served as controls for IT patients. Although Pro.V.A subjects were older than IT patients (73.9±6.7 vs 54.1±13.0 years old, p<0.05), the distribution among clinically defined 25-OHD ranges was nearly identical (table 1) . Results showed a comparable or lower prevalence of reduced endogenous vitamin D levels compared with that in the corresponding general populations, that is, the prevalence of vitamin D insufficiency or deficiency was not increased among patients with sarcoidosis.
Effect of vitamin D repletion
Sixteen US patients with reduced baseline 25-OHD levels (<75 nmol/L) agreed to be treated with ergocalciferol for 12 weeks. Baseline serum calcium, 25-OHD, urinary Ca/Cr ratio and 1,25-(OH) 2 D were compared with that obtained at the end of therapy ( figure 2 and table 4) . Following repletion, the serum 25-OHD level rose in 15 of the 16 patients (average from 42±12 to 82±25 nmol/L, p<0.0001) while remaining essentially unchanged in 1 patient (table 4). The mean ionized serum calcium level was unchanged (from 1.33±0.05 to 1.33±0.09 mmol/L, p=0.67), although 2 patients developed mildly and transiently increased ionized serum calcium postrepletion above normal range (from 1.38 to 1.50 mmol/L and from 1.30 to 1.48 mmol/L). In one of these 2 patients, postrepletion serum total calcium (2.40-2.78 mmol/L), urinary calcium (2.47 to 11.85 mmol/24 h), and urinary Ca/Cr ratio (0.24 to 0.77 mmol/mmol) also mildly exceeded normal limits. In the other patient with elevated postrepletion serum ionized Ca 2+ level, serum total calcium remained normal (from 2.38 to 2.55 mmol/L) while 24 h urinary Ca/Cr ratio was abnormally elevated both pre-repletion and postrepletion (from 0.73 to 0.79 mmol/mmol). In a third patient who showed significant postrepletion increases in serum 25-OHD (from 25 to 150 nmol/L), an increase in urinary calcium (from 2.74 to 6.06 mmol/24 h) and a large decrease in urinary creatinine (from 8.09 to 2.87 mmol/ 24 h) led to a significant increase in urinary Ca/Cr ratio (from 0.34 to 2.11 mmol/mmol) while serum total and ionized calcium remained within normal ranges (from 2.40 to 2.23 mmol/L and 1.25 to 1.33 mmol/L, respectively). Thus, in total, 3 patients developed increased blood and/or urine calcium indices as a result of vitamin D repletion; the increases were mild, asymptomatic, and reversible.
Unexpectedly, average serum 1,25-(OH) 2 D levels of 16 US patients declined significantly postrepletion from 101 ±31 to 52±23 pmol/L ( p<0.0001). An absolute decrease was observed in 14 of the 16 US patients, whereas serum level did not change in 2 of the 16 patients (figure 2).
There was no difference in the pre-repletion to postrepletion change in serum calcium ( p=0.81), 25-OHD ( p=0.68), or 1,25-(OH) 2 D ( p=0.86) levels between patients who were taking prednisone (n=6) and those not taking prednisone (n=10).
Serum ACE and γ-globulin levels were also affected following vitamin D repletion. Taking all treated patients together, the serum ACE level declined slightly but not significantly from pre-repletion to postrepletion (1106±687 to 1005±469 nKat/L, p=0.09). However, in the subgroup of nine US patients with elevated baseline ACE levels, their ACE levels declined significantly from pre-repletion to postrepletion (1524±553 to 1240±352 nKat/L, p=0.04). Serum γ-globulins also decreased slightly but significantly from pre-repletion to postrepletion (1.8±0.6 to 1.6±0.6 g/dL, p=0.002) (table 4). Bone-specific alkaline phosphatase was not significantly affected by repletion (from 93±44 to 92±39 mg/L, p=0.81).
Pulmonary function changed variably from pre-vitamin D to post-vitamin D repletion. There were no significant 
DISCUSSION
This prospective study compared calcium and vitamin D homeostasis in two ethnically and geographically distinct populations with sarcoidosis. The US patients were mostly AA (93%) and female (89%), compared to Italian subjects (95% Caucasians, 62% female). Fewer US patients were on prednisone treatment than IT patients, and US patients had worse FVC, FEV 1 and DL CO than IT patients. There are several salient discoveries: First, patients with sarcoidosis with vastly different ethnic and lifestyle backgrounds appear to be similar in clinical and biochemical parameters. Second, nephrolithiasis is common in patients with sarcoidosis and is largely driven by hypercalciuria, but the urinary calcium excretion rate is not significantly associated with serum vitamin D levels. Third, calcium & vitamin D parameters do not differ between patients taking glucocorticoids versus those not taking glucocorticoids, except that glucocorticoid-treated IT patients had higher urinary calcium excretion. Fourth, the prevalence of vitamin D insufficiency is lower in AA patients than in the general AA population and not different between IT patients with sarcoidosis and the general IT population. Fifth, there is an inverse relationship between the changes in 25-OHD levels and changes in 1,25-(OH) 2 D following repletion of vitamin D levels. Sixth, repletion of vitamin D stores in sarcoidosis is generally safe and effective; mild asymptomatic reversible hypercalcemia and/or hypercalciuria infrequently develop during treatment.
Prevalence of nephrolithiasis in sarcoidosis in the literature ranges between 1.3 and 14% 9 21-25 and hypercalciuria (>5.0 mmol/24 h) has been demonstrated in more than half of the patients with sarcoidosis on an average calcium intake of 10.0 mmol/24 h. 21 In our study, 7/42 Italian (17%) and 5/44 US (11%) patients had kidney stones compared to the general Italian and US population prevalence of 7.5% and 8%, respectively. 26 27 Basal levels of serum 25-OHD did not differ between these two groups. Urinary calcium excretion was higher in kidney stone formers than non-kidney stone formers, but did not bear any significant relationship to serum 25-OHD and 1,25-(OH) 2 D. This vitamin D-independent hypercalciuria in the sarcoidosis population may reflect an impairment in renal tubular calcium reabsorption, 9 and possibly renal tubular interstitial involvement by sarcoidosis. [28] [29] [30] [31] In IT patients, lower endogenous 25-OHD and 1,25-(OH) 2 D levels were observed in glucocorticoidtreated patients, accompanied by higher urinary calcium excretion, suggesting possible bone loss. In US patients, there were no differences in calcium & vitamin D parameters between glucocorticoid-treated patients and non-glucocorticoid-treated patients. However, US patients had lower FVC, FEV 1 and DL CO (% predicted), and glucocorticoid-treated US patients had lower FVC, FEV 1 and DL CO (% predicted) compared to the corresponding (table 3) .
As expected, the prevalence of reduced 25-OHD levels was higher among US AA patients than among IT Caucasian patients; the difference mirrors that in the respective general populations (table 1). The prevalence of vitamin D deficiency was lower in US patients with sarcoidosis than in the general AA population.
Our prospective data indicate that vitamin D supplementation for 3 months in vitamin D-deficient patients with sarcoidosis is effective in repletion of vitamin D stores and generally safe, although mild elevation of serum and urinary calcium levels may develop; thus, calcium balance should be monitored in all patients during vitamin D supplementation. Our results are consistent with the findings of a retrospective study of 301 patients with sarcoidosis that calcium (500 mg daily) and vitamin D (400 IU daily) supplementation did not raise serum calcium concentration. 15 In a short-term prospective study of four patients taking ergocalciferol 10,000 IU daily for 12 days, urinary calcium rose by 21%, from 3.42 to 4.14 mmol/24 h, 6 which was similar to our observations over 3 months. The variable and modest postrepletion changes we observed in lung function measures at rest are inconclusive. Spirometry indices were unchanged or slightly improved. The reductions in DL CO and V A with a stable DL CO /V A suggest reduced inspired lung volume. A larger cohort with longer treatment duration and measurement of lung volume by plethysmography will be required to draw definitive conclusions regarding lung function changes.
Vitamin D plays a major role in skeletal health, 32 33 as well as in immune-modulation mediating adaptive immunity 34 and suppressing granulomatous inflammation. The serum 25-OHD level is inversely related to sarcoidosis disease activity. 15 An important observation in our study is that serum 1,25-(OH) 2 D decreased markedly by ∼50% in 14/16 patients after 3 months of 25-OHD supplementation (from 101±31 to 52±23 pmol/L, p<0.0001) while remaining unchanged in 2/16 patients. In contrast, an earlier study involving four patients treated with vitamin D2 daily for 12 days reported a mild increase (14%) in plasma 1,25-(OH) 2 D from 75 to 86 pmol/L. 6 In our US patients, baseline serum 1,25-(OH) 2 D was 65% higher (table 2) while measures of lung function (FVC, FEV 1 , FEV 1 /FVC and DL CO ) were 12-30% lower (table 1) than in IT patients, consistent with more severe granulomatous inflammation in the predominantly African American cohort. The marked (average 50%) decrease in serum 1,25-(OH) 2 D level following 25-OHD supplementation may be related to the anti-inflammatory action of vitamin D, which has been shown to enhance innate immunity (eg, promote anti-bactericidal activity) and suppress adaptive immunity (eg, promote anti-inflammation), facilitate antigen elimination, and improve the outcome of granulomatous diseases such as mycobacterial infection through changes in γ interferon and cathelicidin concentrations. [35] [36] [37] The high prevalence of vitamin D deficiency in AA 38 has been reported to predispose to more aggressive M. tuberculosis infection, 35 and vitamin D supplementation has shown significant benefit in treating tuberculosis in vitamin D deficient patients. 35 38-41 In this context, extrarenal production of 1,25-(OH) 2 D in sarcoidosis, particularly in patients with vitamin D deficiency, may be an adaptive response by immune-active cells in an attempt to mitigate antigen-stimulated granulomatous inflammation. In our patients with sarcoidosis, repletion of endogenous vitamin D stores reduces the need for extrarenal 1,25-(OH) 2 D production, and could explain the fall in serum 1,25-(OH) 2 D level. This putative mechanism, while consistent with current understanding of vitamin D homeostasis, will require further studies for validation.
The key strengths of this study include a carefully designed cross-sectional comparison of two ethnically diverse patients' cohorts with their respective ethnic general populations as control and with a subgroup intervention arm (vitamin D supplementation). The key limitations of the study include the small number of patients given vitamin D supplementation. Also, dietary calcium intake was not included in our analysis.
In conclusion, our two populations of patients with sarcoidosis with a diverse genetic background and lifestyle show similar calcium and vitamin D parameters. Compared to the ethnically matched healthy controls, patients with sarcoidosis are not more likely to be vitamin D deficient. The prevalence of nephrolithiasis is higher in patients with sarcoidosis than in the general population. The sole identifiable risk factor for nephrolithiasis, hypercalciuria, is unrelated to the status of vitamin D levels. Repletion of 25-OHD stores in patients with sarcoidosis and vitamin D insufficiency is generally safe, although in a minority of patients' serum and/or urinary calcium levels it may increase above normal; thus, the calcium balance should be monitored during treatment. In patients with an elevated basal serum ACE level, repletion of 25-OHD stores is associated with a consistent decline in ACE level, suggesting suppression of granulomatous immune activity. Repletion of 25-OHD stores is also associated with an unexpected reduction in serum 1,25-(OH) 2 D level, suggesting suppression of autonomous ectopic 1,25-(OH) 2 D production by granuloma-associated immune cells. Whether repletion of 25-OHD mitigates the clinical course of granulomatous inflammation remains to be determined.
